Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm Phase II Study of Bevacizumab Plus Modified FOLFIRINOX Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

NCT05665023 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT05665023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm Phase II Study of Bevacizumab Plus Modified FOLFIRINOX Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Unknown status
Start date
October 28, 2022
Completion date
February 1, 2025
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, mucinous ovarian cancer, primary peritoneal cancer